Vaxcyte, Inc. (PCVX): Total Assets
$3.00B
As of 2025-12-31
$3.14B
As of 2026-06-30
+44.0%
3-year compound annual growth
+50.2%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.00B | -14.5% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $3.51B | +149.4% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $1.41B | +39.9% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $1.01B | +210.2% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $324.34M | -17.4% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $392.83M | +497.9% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $65.70M | n/a | 2021-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | 2025-12-31 | $3.00B | -14.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $2.35B | -8.0% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
Compare PCVX, RGEN, EXEL, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗